

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (Currently Amended) An attenuated, replication competent recombinant human metapneumovirus (rHMPV), comprising a recombinant HMPV genome or antigenome of SEQ ID NO: 1 or SEQ ID NO: 2, comprising one or more attenuating nucleotide modifications including a partial or complete deletion of the rHMPV M2-2 ORF or one or more nucleotide substitutions that ablates expression of the rHMPV M2-2 ORF, and a major nucleocapsid (N) protein, a nucleocapsid phosphoprotein (P), and a large polymerase protein (L) of a HMPV.

2. (Canceled)

3. (Original) The rHMPV of claim 1, wherein the recombinant HMPV genome or antigenome further comprises a detectable heterologous sequence encoding a polypeptide.

4. (Original) The rHMPV of claim 3, wherein the detectable heterologous sequence encodes a reporter.

5. (Original) The rHMPV of claim 4, wherein the reporter comprises green fluorescent protein (GFP).

6. (Previously Presented) The rHMPV of claim 3, wherein the detectable heterologous sequence is operably linked to a HMPV gene transcription start signal and to a HMPV gene end signal.

7.-14. (Canceled).

15. (Previously Presented) The rHMPV claim 1, wherein the one or more attenuating nucleotide modifications comprises one or more nucleotide substitutions that ablates expression of a rHMPV M2-2 ORF.

16. (Previously Presented) The rHMPV of claim 15, wherein the one or more nucleotide substitutions that ablates expression of the rHMPV M2-2 ORF comprises one or more nucleotide substitutions that ablates one or more potential translation initiation codons

of the rHMPV M2-2 ORF or introduces one or more in-frame stop codons into the rHMPV M2-2 ORF.

17.-57. (Canceled)

58. (Previously Presented) The rHMPV of claim 16, that demonstrates a ten-fold or more reduction in growth in the presence of interferon, but is not attenuated when growing in the absence of interferon.

59. (Previously Presented) The rHMPV of claim 18, that demonstrates a ten-fold or more reduction in growth in the presence of interferon, but is not attenuated when growing in the absence of interferon.

60.-61. (Canceled)